论文部分内容阅读
探讨地西他滨(DAC)治疗老年骨髓增生异常综合征患者临床疗效及与免疫淋巴细胞计数的关系.[方法]选择2014年3月至2016年5月于本院接受治疗的老年骨髓增生异常综合征患者63例作为研究对象.根据患者DAC首次治疗后28d的淋巴细胞计数绝对值将患者分为高淋巴细胞组(H-Lym组,27例,淋巴细胞计数绝对值≥1.2×109/L)和低淋巴细胞组 (L-Lym组,36例,淋巴细胞计数绝对值0.05).However,thelymphocytecountsintheL-Lymgroupafterthefirstcourseof DACtreatmentweresignificantlylowerthanthoseinthediagnosis (P<0.05).(3)TheORRofthe H-Lym groupwas81.48%,whichwassignificantlyhigherthanthatoftheL-Lymgroup(38.89%)(P<0.05).Patients intherelativelyhigh-riskgroupweremorelikelytorespondtoDACtherapythanpatientswitharelativelylow-riskgroupofIPSS (P<0.05).(4)The medianPFSvalueofpatientsinthe H-Lym group was10.7 months (95% CI,7.9~13.5months),whichwassignificantlyhigherthanthatoftheL-Lym group8.1 months (4.3to 11.9months)(P<0.05).Correlationanalysisshowedthathighlymphocytecountwasariskfactorfordifference inPFSbetweenthetwogroups.[Conclusion]Patientswithabsolutelymphocytecount≥1.2×109/Lonthe28th dayafterthefirsttreatmentofDAChavehighertotalresponserate(ORR)andprogression-freesurvival(PFS), whichcanbeusedforearlypredictionofDACresponse.